Mass Specs, M&A, and Pharma on the Rebound: Proteomics Outfits Speak at UBS Conference | GenomeWeb
This week’s UBS Global Life Sciences Conference in New York served as a platform for some of the top proteomic tool vendors — including Waters, Thermo Fisher Scientific, Bruker BioSciences, Invitrogen, and Applied Biosystems — to showcase their businesses for the Wall Street community. Some spoke about the positive impact of a revitalized pharmaceutical market, while others provided an update on their mass spectrometry businesses and others outlined their acquisition strategies.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.